Group 1 - The core viewpoint of the news highlights the recent stock performance and financial metrics of Fosun Pharma, indicating a decline in stock price and significant net outflow of funds [1][2] - As of September 19, Fosun Pharma's stock price decreased by 2.02% to 30.97 CNY per share, with a total market capitalization of 82.703 billion CNY [1] - The company has seen a year-to-date stock price increase of 26.24%, but a recent decline of 1.74% over the last five trading days [1] Group 2 - Fosun Pharma's main business segments include drug manufacturing and research, with a revenue composition of 45.68% from anti-tumor and immune regulation products, 17.53% from anti-infection products, and 13.83% from metabolic and digestive system products [1] - For the first half of 2025, Fosun Pharma reported a revenue of 19.514 billion CNY, a year-on-year decrease of 4.63%, while the net profit attributable to shareholders increased by 38.96% to 1.702 billion CNY [2] - The company has distributed a total of 12.593 billion CNY in dividends since its A-share listing, with 2.691 billion CNY distributed in the last three years [3]

资金流向方面，主力资金净流入2087.90万元，特大单买入9400.74万元，占比11.73%，卖出9449.59万 元，占比11.79%；大单买入2.05亿元，占比25.64%，卖出1.84亿元，占比22.97%。 复星医药今年以来股价涨31.09%，近5个交易日涨0.25%，近20日涨12.72%，近60日涨32.22%。 资料显示，上海复星医药(集团)股份有限公司位于上海市宜山路1289号A楼,香港铜锣湾希慎道33号利园 1期19楼1917室，成立日期1995年5月31日，上市日期1998年8月7日，公司主营业务涉及药品制造与研发 为核心,业务覆盖医疗器械与医学诊断、医疗服务、医药分销与零售。主营业务收入构成为：抗肿瘤及 免疫调节核心产品45.68%，抗感染核心产品17.53%，代谢及消化系统核心产品13.83%，心血管系统核 心产品9.80%，原料药和中间体核心产品6.43%，中枢神经系统核心产品5.21%，其他业务收入1.52%。 9月15日，复星医药盘中上涨2.03%，截至10:53，报32.16元/股，成交8.01亿元，换手率1.19%，总市值 858.81亿元。 截至6月30日，复星医药股东户 ...